Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYZ57N)

• Drug Name: Albendazole Drug Info
• Synonyms: Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole

Indication

Disease Entry	ICD 11	Status	REF
Echinococcus granulosus infectious disease		Approved	[1]
Helminth infection	1F90.0	Approved	[1]
Worm infection	1F90.Z	Approved	[2]

• Therapeutic Class: Antiprotozoal Agents
• Cross-matching ID:
  PubChem CID: 2082
  ChEBI ID: CHEBI:16664
  CAS Number: CAS 54965-21-8
  TTD Drug ID: DMYZ57N
  VARIDT Drug ID: DR01323
  INTEDE Drug ID: DR0055
  ACDINA Drug ID: D00015

Molecule-Related Drug Atlas

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[16]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[3]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[18]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[19]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[21]
Lexibulin	DMLEX1D	Glioblastoma multiforme	2A00.0	Phase 2	[22]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[23]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[24]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[25]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[26]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[25]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[25]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[27]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[28]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[29]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[30]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[31]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[32]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[33]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[34]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[36]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[37]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[31]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[38]

Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[39]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[40]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[41]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[42]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[43]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[44]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[36]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[45]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[46]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[47]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[58]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[58]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[58]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[59]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[60]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[61]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[62]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[63]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[64]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[65]

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[48]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[49]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[50]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[51]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[52]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[53]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[54]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[55]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[56]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[57]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[7]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[10]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[66]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[67]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[69]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[70]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[71]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[72]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[73]

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[74]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[75]
Fructose	DM43AN2	Vomiting	MD90	Approved	[65]
Ketoprofen	DMRKXPT	Bursitis		Approved	[65]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[76]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[77]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[78]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[79]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[81]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[82]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[84]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[85]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[86]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[87]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[88]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[90]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[91]

Drug(s) Affected By Interleukin-6 receptor subunit alpha (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[92]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[94]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[8]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[99]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[100]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[101]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[102]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[103]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[104]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[105]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[106]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[107]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[108]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[109]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[107]

Drug(s) Affected By Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[110]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[111]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[13]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[94]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[114]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[97]

Drug(s) Affected By C-C motif chemokine 2 (CCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[116]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[117]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[118]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[81]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[119]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[120]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[121]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[83]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[123]

Drug(s) Affected By HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[114]
Valdecoxib	DMAY7H4	Osteoarthritis	FA00-FA05	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[12]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[125]
Vancomycin	DM3JFIH	Bacteremia	1A73	Approved	[12]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[126]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[127]
Bortezomib	DMNO38U	Leukemia		Approved	[128]

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[11]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[11]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[130]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[131]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[11]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[94]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[11]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[11]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[11]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[10]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[132]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[133]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[134]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[135]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[136]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[137]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[138]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[139]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[104]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Binder	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[8]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[7]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[7]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[10]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[11]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[12]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Gene/Protein Processing	[8]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[8]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Gene/Protein Processing	[13]

References

• [1] Albendazole FDA Label
• [2] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
• [3] Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
• [4] The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
• [5] Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
• [6] Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
• [7] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [8] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [9] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [10] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [11] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [12] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [13] Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
• [16] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [17] NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
• [18] Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
• [19] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [20] Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
• [21] The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
• [22] National Cancer Institute Drug Dictionary (drug id 598799).
• [23] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [24] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [25] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [26] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [27] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [28] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [29] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [30] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [31] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [32] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [33] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [34] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [35] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [36] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [37] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [38] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [39] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [40] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [41] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [42] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [43] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [44] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [45] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [46] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [47] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [48] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [49] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [50] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [51] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [52] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [53] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [54] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [55] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [56] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [57] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [58] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [59] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [60] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [61] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [62] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [63] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [64] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [65] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [66] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [67] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [68] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [69] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [70] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [71] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [72] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [73] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [74] Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
• [75] A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
• [76] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [77] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [78] Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
• [79] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [80] Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
• [81] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [82] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [83] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [84] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [85] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [86] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [87] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [88] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [89] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [90] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [91] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [92] Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells. Int J Mol Sci. 2017 Jan 28;18(2):271. doi: 10.3390/ijms18020271.
• [93] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [94] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [95] In vitro antitumoral effects of the steroid ouabain on human thyroid papillary carcinoma cell lines. Environ Toxicol. 2021 Jul;36(7):1338-1348. doi: 10.1002/tox.23130. Epub 2021 Mar 24.
• [96] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [97] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [98] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [99] Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J. 1991 Aug 1;277 ( Pt 3)(Pt 3):659-64. doi: 10.1042/bj2770659.
• [100] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [101] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [102] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [103] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [104] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [105] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [106] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [107] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [108] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [109] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [110] Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
• [111] The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010;12(3):R43. doi: 10.1186/bcr2598. Epub 2010 Jun 28.
• [112] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [113] Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
• [114] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [115] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [116] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [117] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [118] Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
• [119] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [120] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [121] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [122] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
• [123] Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
• [124] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [125] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [126] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [127] Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res. 2005 Sep 1;11(17):6352-8. doi: 10.1158/1078-0432.CCR-04-1931.
• [128] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [129] NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
• [130] Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
• [131] Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
• [132] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [133] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [134] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [135] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [136] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [137] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [138] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [139] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.